IL6 and neoplasm: In the case of IL-6, circulating levels remained all but undetectable in patients displaying tumor response throughout the entire follow-up period, with a baseline median of IL-6: 0 (IQR, 2.22) vs. 4.5 pg/mL (IQR, 5.1), p-value=0.072 (see Figure 2D).